Jennifer Valerin | UCI Health | Orange ...

Dr. Jennifer B. Valerin

Claim this profile

UC Irvine Health/Chao Family Comprehensive Cancer Center

Expert in Pancreatic Cancer
Studies Lung Cancer
19 reported clinical trials
35 drugs studied

Area of expertise

1Pancreatic Cancer
Global Leader
Jennifer B. Valerin has run 11 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
BRCA1 positive
BRCA2 positive
2Lung Cancer
Jennifer B. Valerin has run 6 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
HER2 positive
Stage III

Affiliated Hospitals

Image of trial facility.
UC Irvine Health/Chao Family Comprehensive Cancer Center
Image of trial facility.
UCI Health - Chao Family Comprehensive Cancer Center And Ambulatory Care

Clinical Trials Jennifer B. Valerin is currently running

Image of trial facility.

Nivolumab + Ipilimumab + Sargramostim

for Advanced Melanoma

This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
Image of trial facility.

Durvalumab + Olaparib with Radiation

for Pancreatic Cancer

This phase I trial tests the safety and tolerability of olaparib in combination with durvalumab and radiation therapy in patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable). Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. The combination of targeted therapy with olaparib, immunotherapy with durvalumab and radiation therapy may stimulate an anti-tumor immune response and promote tumor control in locally advanced unresectable pancreatic cancer.
Recruiting1 award Phase 125 criteria

More about Jennifer B. Valerin

Clinical Trial Related5 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 9 Active Clinical Trials
Treatments Jennifer B. Valerin has experience with
  • Nivolumab
  • Nab Paclitaxel
  • Pembrolizumab
  • Olaparib
  • Gemcitabine
  • Fluorouracil

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Jennifer B. Valerin specialize in?
Is Jennifer B. Valerin currently recruiting for clinical trials?
Are there any treatments that Jennifer B. Valerin has studied deeply?
What is the best way to schedule an appointment with Jennifer B. Valerin?
What is the office address of Jennifer B. Valerin?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security